Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K. Paik, Xiuning Le, Hélène Senellart et al.|New England Journal of Medicine|2020Cited by 879
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi‐Long Wu, Tae Min Kim, Valentina Guarneri et al.|The Lancet Oncology|2024Cited by 98
<i>MET</i>ex14 ctDNA dynamics & resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with <i>MET</i>ex14 skipping NSCLC treated with tepotinib.Paul K. Paik, Xiuning Le, Rémi Veillon et al.|Journal of Clinical Oncology|2021Cited by 7
METex14 ctDNA Dynamics & Resistance Mechanisms Detected in Liquid Biopsy (LBx) From Patients (pts) With METex14 Skipping NSCLC Treated With TepotinibP. Paik, Xiao‐Feng Le, R. O'Hara et al.|International Journal of Radiation Oncology*Biology*Physics|2022Cited by 0